Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

rally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions.  Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2013.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statem
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... ST. LOUIS , Sept. 18, 2014 /PRNewswire/ ... ) announced today it has entered into a ... Michigan (U-M) Medical School,s Vector Core. Under the ... Sigma CRISPR technology, experimental design consultation, and dedicated ... poised to accelerate gene editing-based research at the ...
(Date:9/18/2014)... loss and diabetes prevention, could actually hasten the development ... it in a surprising way: by changing the composition ... population of bacteria residing in our intestines. These findings, ... published today in Nature . Among other things, ... Department, who led this research together with Prof. Eran ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 ... which include Sartorius/Biohit, Socorex, Capp, and AccuPet brand ... volumes of 100 uL or less and are ... and forensic applications. , The micropipette promotions ... quality and economic alternative products to help customers ...
(Date:9/17/2014)... Sept. 17, 2014 The global consumption of squalene ... Squalene is a natural skin-identical chemical that finds applications in ... food supplements, pharmaceuticals, and in other applications like high grade ... has a few major players and is regionally segregated. Sophim ... Liver Oil Co. Ltd. ( Japan ), SeaDragon ...
Breaking Biology Technology:Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... generation design reduces the amount of retraction needed for surgical ... ... 23 Pioneer Surgical Technology,today announces the market availability of the ... cervical fusion procedures while addressing the clinical needs of,anterior cervical discectomy ...
... Technology,Inc. (Nasdaq: EFUT ) (,eFuture,), a leading ... to China,s retail and consumer goods,industries, today announced ... its,mySHOP Retail Business Management System 3.0 (,mySHOP 3.0, ... Group,). eFuture will install,the system at Tiens Group,s ...
... company enters into a strategic supply chain agreement in preparation for ... ... July 23, 2008 -- CN Probes , an emerging nanotech ... (contract manufacturer). This agreement puts CN Probes closer to ramping up ...
Cached Biology Technology:Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System 2eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 2eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 3eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 4eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 5Carbon Nanoprobes, Inc Announces Production Agreement With Leading MEMS Foundry 2Carbon Nanoprobes, Inc Announces Production Agreement With Leading MEMS Foundry 3
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical Center ... circulating protein apolipoprotein E, called apoE3, helps repair the ... apoE4, do not get the benefit of this repair, ... "We believe that we have identified one mechanism by ... a genetic variant, apoE4, is detrimental," said Dr. ...
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/17/2014)... the United Kingdom forms a new crime unit designed ... uproar last year over horse meat being passed off ... technique for detecting meat adulteration. They describe their approach, ... ACS, Journal of Agricultural and Food Chemistry . ... is a major global economic problem. But they also ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... issue of the Journal of General Physiology ... of British Columbia, Vancouver) and colleagues that explores pore ... in vivo nonsense suppression technology. The study will be ... to Riccardo Olcese (UCLA) in a commentary accompanying the ...
... in DNA sequencing make determining how living things ... which their genes have been rearranged on chromosomes. ... requires massive computing impossible even on the most ... $1 million project, funded by the National Science ...
... in high-throughput DNA sequencing have opened up the ... by analyzing the ways in which their genes ... evolutionary relationships from rearrangement events is computationally intensive ... today. Research recently funded by the American ...
Cached Biology News:Petascale computational tools could revolutionize understanding of genomic evolution 2Petascale computing tools could provide deeper insight into genomic evolution 2Petascale computing tools could provide deeper insight into genomic evolution 3
... Normal;heading 1;heading ... types and experimental ... for standard transfection ... transduction systems. ViraPower ...
... Product Rabbit polyclonal to ... conjugated to KLH, corresponding to amino ... / Specificity Cross-reacts with Rat.Expected to ... Mouse (100% identity with immunogen), Rabbit (100% ...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Inventory Racks for cryogenic vials. ... cardboard or stainless steel boxes ... cryo vials. Vapor phase ... Platform risers to be ...
Biology Products: